AL amyloidosis market seen reaching $6.38 billion by 2030

The Business Research Company projects the global AL amyloidosis market will grow from $3.97 billion in 2026 to $6.38 billion by 2030, driven by targeted therapies, broader use of monoclonal antibodies and proteasome inhibitors, and earlier diagnosis. North America held the largest share in 2025, reflecting stronger diagnostics, higher awareness and more established care infrastructure.

Why it matters: - AL amyloidosis is a rare, serious disease that can damage the heart, kidneys, liver and nervous system. - Market growth signals more investment in diagnostics, supportive care and therapies for a condition that has been difficult to treat. - Earlier detection and newer treatments could improve outcomes for patients with organ involvement.

What happened: - The Business Research Company released its AL Amyloidosis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the AL amyloidosis market will rise from $3.51 billion in 2025 to $3.97 billion in 2026, a 13.0% CAGR. - The market is forecast to reach $6.38 billion by 2030, growing at a 12.6% CAGR. - The report was published Oct. 30, 2026. - A free sample of the report is available. - A full version of the report is also available.

The details: - AL amyloidosis develops when plasma cells in the bone marrow produce abnormal light chain proteins. - Those misfolded proteins form amyloid fibrils that deposit in tissues and organs, disrupting normal function. - Common symptoms include fatigue, swelling, shortness of breath, numbness and other signs of organ dysfunction. - The report links recent market growth to limited treatment options, heavy reliance on traditional chemotherapy, low patient awareness, weak organ-specific supportive care and limited access to specialized treatment centers. - Future growth is expected to be supported by innovative targeted therapies, broader use of monoclonal antibodies and proteasome inhibitors, expansion in stem cell transplant programs, better rare-disease infrastructure and advanced diagnostic technologies. - The report highlights greater adoption of targeted treatments, more organ-specific supportive care and higher awareness that could drive earlier diagnosis. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The projected expansion reflects a broader shift from late-stage disease management toward earlier detection and more precise treatment. - Rising incidence of plasma cell disorders is a key demand driver because AL amyloidosis stems from those conditions. - The American Cancer Society projected about 35,780 new U.S. multiple myeloma cases in 2024, including 19,520 men and 16,260 women, with about 12,540 deaths. - Multiple myeloma is a major plasma cell disorder, so rising case counts point to a larger pool of patients at risk for AL amyloidosis. - The report’s regional split suggests the market remains strongest where diagnostic access and specialist care are already more developed.

What's next: - More drug development is likely to focus on targeted therapies and combinations that can reduce organ damage sooner. - Diagnostic improvements should continue pushing diagnosis earlier in the disease course. - The report expects continued expansion in stem cell transplant programs and supportive care for affected organs. - The Business Research Company says updated market tools in the report include TAM analysis, company scoring matrices, forecasting dashboards, hotspots infographics and trend analysis. - The company provided contact details for further inquiries and promoted its social media channels, including LinkedIn, Facebook and X.